Early trial of PF-08046031 for advanced cancers ends early

NCT ID NCT06799533

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-08046031 (a drug given into the vein)
What this could lead to: If it works, this could point toward a new treatment option for advanced melanoma and other solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 11 participants, and it was terminated early, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma esophageal cancer head and neck squamous cell carcinoma melanoma metastatic melanoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA MELANOMA METASTATIC MELANOMA SOLID TUMORS

Contacts and locations

Locations

Gustave Roussy

Villejuif, Val-de-marne, 94800, France
Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [barcelona], 08035, Spain
Karolinska Universitetssjukhuset Solna

Solna, Stockholms LÄN [se-01], 171 64, Sweden
Presbyterian/ St. Lukes Medical Center

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute at HealthONE - SCRI - PPDS

Denver, Colorado, 80218, United States
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate

Los Angeles, California, 90025, United States
The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate

Los Angeles, California, 90025, United States
The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only)

Santa Monica, California, 90404, United States
The Royal Marsden NHS Foundation Trust

Sutton, SM2 5PT, United Kingdom
UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94143, United States
UCSF Medical Center, Investigational Pharmacy

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.